A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes

References

• Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
   PubMed Web of Science ®Google Scholar
• Fonseca VA. Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. Am J Med 2007;120(9 Suppl 2):S18-25
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7
   PubMed Web of Science ®Google Scholar
• Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29:12-20
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-8
   Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009;373:2125-35
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73
   PubMed Web of Science ®Google Scholar
• Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: systematic review and meta-analysis. CMAJ 2008 Dec 10
   Google Scholar
• Triscari JD, C, Isaacsohn J. Glucose levels in type 2 diabetics treated for 6 weeks with rivoglitazone HCl. Diabetes 2006;55(Suppl 1):A132
   Google Scholar
• Truitt K, Chou HS, Wang A. A randomized multiple-dose, placebo-controlled comparative study of rivoglitazone and open-label pioglitazone in patients with type 2 diabetes. Diabetes 2006;57(Suppl 1):437P
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19
   PubMed Web of Science ®Google Scholar
• Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968-74
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2008. Diabetes Care 2008;31(Suppl 1):S12-54
   Google Scholar
• Peters Harmel AL, Kendall DM, Buse JB, et al. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004;20:215-23
   PubMed Web of Science ®Google Scholar
• Leonhardt W, Pfutzner A, Muller J, et al. Effects of pioglitazone and/or simvastatin on low density lipoprotein subfractions in non-diabetic patients with high cardiovascular risk: a sub-analysis from the PIOSTAT study. Atherosclerosis Mar 26, 2008
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. 2008 [cited February 17, 2009]; Available from: http://www.fda.gov/Cder/Guidance/8576fnl.pdf
   Google Scholar
• Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
   PubMed Web of Science ®Google Scholar
• Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-10
   PubMed Web of Science ®Google Scholar